Eli Lilly and Company (NYSE:LLY) Shares Sold Rep. Dan Newhouse

Representative Dan Newhouse (Republican-Washington) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on July 17th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on July 10th. The trade occurred in the Representative’s “EDWARD JONES IRA” account.

Representative Dan Newhouse also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 7/10/2026.
• Sold $1,001 – $15,000 in shares of Deere & Company (NYSE:DE) on 7/10/2026.
• Purchased $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 7/10/2026.
• Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 7/10/2026.
• Sold $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 7/10/2026.
• Purchased $1,001 – $15,000 in shares of Duke Energy (NYSE:DUK) on 7/10/2026.
• Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 7/10/2026.
• Sold $1,001 – $15,000 in shares of Fortinet (NASDAQ:FTNT) on 7/10/2026.
• Sold $1,001 – $15,000 in shares of Magna International (NYSE:MGA) on 7/10/2026.
• Purchased $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 7/10/2026.

Eli Lilly and Company Price Performance

NYSE LLY traded up $14.56 during trading hours on Tuesday, hitting $1,161.46. 887,335 shares of the company’s stock traded hands, compared to its average volume of 3,161,225. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm’s 50-day moving average is $1,122.49 and its 200-day moving average is $1,036.98. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a market capitalization of $1.09 trillion, a PE ratio of 41.20, a PEG ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 34.55 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ballast Inc. increased its stake in Eli Lilly and Company by 10.9% in the second quarter. Ballast Inc. now owns 4,427 shares of the company’s stock valued at $5,310,000 after acquiring an additional 434 shares during the last quarter. Regent Peak Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 4.2% during the second quarter. Regent Peak Wealth Advisors LLC now owns 2,995 shares of the company’s stock worth $3,592,000 after purchasing an additional 120 shares during the last quarter. Northside Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.0% in the 2nd quarter. Northside Capital Management LLC now owns 20,894 shares of the company’s stock valued at $25,061,000 after purchasing an additional 618 shares in the last quarter. Annex Advisory Services LLC increased its stake in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. Annex Advisory Services LLC now owns 3,835 shares of the company’s stock valued at $4,599,000 after purchasing an additional 60 shares during the last quarter. Finally, Insight Wealth Strategies LLC raised its holdings in shares of Eli Lilly and Company by 5.8% during the 2nd quarter. Insight Wealth Strategies LLC now owns 273 shares of the company’s stock worth $325,000 after buying an additional 15 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. Sanford C. Bernstein boosted their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Finally, Wolfe Research reiterated an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,283.64.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor focus remains on Eli Lilly’s strong long-term GLP-1 growth story, with analysts still highlighting its leadership in obesity drugs, pipeline expansion, and solid growth outlook as key reasons the stock has stayed well-supported.
• Neutral Sentiment: Several market commentary pieces framed LLY as a premium large-cap healthcare name that has outperformed over time, but did not point to any immediate change in fundamentals or guidance.
• Negative Sentiment: Novo Nordisk filed a federal lawsuit accusing Eli Lilly of false and misleading advertising for Zepbound and Mounjaro, claiming Lilly used outdated clinical trial data to make its weight-loss and diabetes drugs appear more effective than Novo’s Wegovy and Ozempic. The suit seeks to stop the ads, force corrective marketing, and recover damages. Reuters article
• Negative Sentiment: The lawsuit may raise the risk of legal costs, forced ad changes, and added competitive pressure in the fast-growing obesity-drug market, which could weigh on sentiment until the dispute is resolved.

About Representative Newhouse

Dan Newhouse (Republican Party) is a member of the U.S. House, representing Washington’s 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Newhouse (Republican Party) ran for re-election to the U.S. House to represent Washington’s 4th Congressional District. He won in the general election on November 5, 2024.

Click here to see Newhouse’s key votes in Congress.

Newhouse served as a member of the Washington House of Representatives representing District 15-Position 2 from 2003 through 2009 and as Washington Director of Agriculture from 2009 to 2013.

Newhouse was first elected to the state House in 2002 and served until he was named state Director of Agriculture in 2009. He was first appointed by Governor Christine Gregoire on February 18, 2009.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.